Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma — Stella

Home/B Cell Lymphoma/Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma

View on ClinicalTrials.gov

Recruiting

Back to B Cell Lymphoma trials

Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Washington University School of Medicine, St Louis, Missouri

Key details

Phase

Early testing

Sponsor

Washington University School of Medicine

Collaborators

Genentech, Inc.

Enrollment target

~15 participants

Started

December 2022

Primary completion

January 2027

Age range

18 Years and older

Last updated April 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.